Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present
Daniel J. Tenney(Bristol-Myers Squibb (Germany)), Richard J. Colonno(Assembly Biosciences (United States)), Steven M. LeVine(Kaiser Permanente Oakland Medical Center), Sharon Zhang(Bristol-Myers Squibb (United States)), Patricia Poundstone(Bristol-Myers Squibb (United States)), Mary Jane Plym(Bristol-Myers Squibb (United States)), Charles E. Mazzucco(Bristol-Myers Squibb (United States)), Ronald E. Rose(Bristol-Myers Squibb (United States)), Betsy J. Eggers(Bristol-Myers Squibb (United States)), Mayla Hsu(Bristol-Myers Squibb (United States)), Joanna Yang(Bristol-Myers Squibb (United States)), Carl J. Baldick(Bristol-Myers Squibb (United States)), Kevin A. Pokornowski(Bristol-Myers Squibb (United States)), Cheng-Fang Yu(Bristol-Myers Squibb (United States)), Jie Fang(Chinese Academy of Sciences), Ann W. Walsh(Bristol-Myers Squibb (United States))
Cited by 239
Related Papers
Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy #
|Hepatology|2009|815
Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B
|Gastroenterology|2006|414
Entecavir resistance is rare in nucleoside naïve patients with hepatitis B
|Hepatology|2006|348
Characterization of the Azinomycin B Biosynthetic Gene Cluster Revealing a Different Iterative Type I Polyketide Synthase for Naphthoate Biosynthesis
|Chemistry & Biology|2008|114
Piloting electronic medical record–based early detection of inpatient deterioration in community hospitals
|Journal of Hospital Medicine|2016|96